Featured Research

from universities, journals, and other organizations

New, More Effective Treatment For Toxic Shock Syndrome

Date:
May 22, 2007
Source:
University of Minnesota
Summary:
Researchers have developed a new therapeutic that neutralizes toxic shock syndrome more effectively than other treatments, study suggests. Toxic Shock Syndrome is a rare, life-threatening bacterial infection that can cause multi-organ failure and death.

Researchers at the University of Minnesota and the University of Illinois at Urbana-Champaign have developed a new therapeutic that neutralizes Toxic Shock Syndrome (TSS) more effectively than other treatments.

Toxic Shock Syndrome is a rare, life-threatening bacterial infection that can cause multi-organ failure and death. A major cause of the disease is a superantigen called staphylococcal enterotoxin B (SEB), which is produced by Staphylococcus aureus bacteria. SEB binds to T-lymphocytes in the body causing the release of cytokines, resulting in the dramatic blood pressure drop seen in TSS.

Currently, TSS can be treated with antibiotics to kill the bacteria and antibodies to neutralize SEB. But, as published in the May 21, 2007 issue of Nature Medicine, scientists have engineered a new high-affinity molecule known as V-beta which blocks SEB's ability to bind to T-cells. By targeting the early stages of disease onset, V-beta neutralizes SEB at a rate 2000 times more effective than typical antibody treatment.

"The development and efficacy of V-beta in animal models is a very significant advancement in infectious disease treatment," said Patrick Schlievert, Ph.D., co-author of the paper and professor of microbiology at the University of Minnesota Medical School. "It represents an easily produced, potential treatment for diseases caused by SEB and other superantigens associated with TSS."

Schlievert and colleague Marnie Peterson, Pharm.D., Ph.D., co-author and assistant professor at the University of Minnesota College of Pharmacy Department of Experimental and Clinical Pharmacology, studied the effects of V-beta on SEB in rabbit models. The treatment of rabbits with SEB was successful when given V-beta following onset of disease, after SEB had caused a high fever and symptoms of TSS, and after rabbits had been exposed to SEB on a continuous basis.

"Not only is SEB a major cause of Toxic Shock Syndrome, it also is considered a potential biological weapon," explained Schlievert. "With that in mind, the small amount of V-beta needed for SEB neutralization makes this a truly significant discovery and useful therapy."

Approximately 3 out of every 100,000 people will get TSS annually. In addition, nearly 35,000 people die every year from post influenza infection, which is often caused by TSS or pneumonia. Symptoms of TSS include high fever, low blood pressure, vomiting and diarrhea, and a rash that looks similar to sunburn. While the infection often occurs in menstruating women and is associated with the use of superabsorbent tampons and contraceptive items, it can also affect men, children and postmenopausal women, particularly following respiratory viral infections. Other risk factors include skin wounds and surgery.

This study was supported by the National Institutes of Health.


Story Source:

The above story is based on materials provided by University of Minnesota. Note: Materials may be edited for content and length.


Cite This Page:

University of Minnesota. "New, More Effective Treatment For Toxic Shock Syndrome." ScienceDaily. ScienceDaily, 22 May 2007. <www.sciencedaily.com/releases/2007/05/070521140852.htm>.
University of Minnesota. (2007, May 22). New, More Effective Treatment For Toxic Shock Syndrome. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2007/05/070521140852.htm
University of Minnesota. "New, More Effective Treatment For Toxic Shock Syndrome." ScienceDaily. www.sciencedaily.com/releases/2007/05/070521140852.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins